UNC Lineberger Comprehensive Cancer Center
Where Charles Perou defined the PAM50 intrinsic subtypes of breast cancer; a public university centre with in-house CAR-T manufacturing.
NCI-designated since 1975 and comprehensive since 1990, UNC Lineberger is a public-university cancer centre with a statewide remit across North Carolina. Charles Perou's intrinsic subtypes and the PAM50 assay reshaped breast cancer classification; Norman Sharpless, later NCI director, worked on CDK4/6 and cellular senescence here and co-founded G1 Therapeutics. Gianpietro Dotti and Barbara Savoldo run one of the few academic in-house CAR-T programmes, and Ethan Basch's patient-reported outcome trials changed how symptoms are monitored during chemotherapy. Blossom Damania and Dirk Dittmer lead research on Kaposi sarcoma herpesvirus and virus-associated cancers.
- Breast cancer subtyping (PAM50)
- Academic CAR-T
- Patient-reported outcomes
- Viral oncology
Pages like this
not linked directly; found by shared links- IdeaMake skipping radiotherapy the default for very low-risk breast cancer
Shares PAM50 / intrinsic subtypes, Toxicity and quality of life are undervalued, HR-positive / HER2-negative breast cancer.
- InstitutionSOLTI Cancer Research Group
Shares PAM50 / intrinsic subtypes, CDK4/6 inhibitors, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonRose Kushner
Shares Patients lack understanding, navigation and agency, National Cancer Institute (NIH), Toxicity and quality of life are undervalued.
- IdeaProspective arm-volume surveillance to catch and reverse lymphoedema early
Shares Toxicity and quality of life are undervalued, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- InstitutionComprehensive Cancer Center Vienna – Medical University of Vienna / AKH
Shares CDK4/6 inhibitors, Diffuse large B-cell lymphoma, CAR-T cell therapy, HR-positive / HER2-negative breast cancer.
- InstitutionSkåne University Hospital / Lund University Cancer Centre
Shares PAM50 / intrinsic subtypes, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- IdeaPaid community advisory boards with power to change protocol burden
Shares Patients lack understanding, navigation and agency, National Cancer Institute (NIH).
- TechnologyExercise during chemotherapy and radiotherapy
Shares Toxicity and quality of life are undervalued, Diffuse large B-cell lymphoma, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.